Latest news with #IntuitiveSurgical
Globe and Mail
5 days ago
- Business
- Globe and Mail
Is ISRG's Procedure Growth Enough to Offset Margin Pressures in 2025?
Intuitive Surgical ISRG entered 2025 with strong operational momentum, delivering 17% year-over-year growth in da Vinci procedures and a 19% rise in total revenues (to $2.25 billion) in the first quarter. Notably, day-adjusted procedure growth reached 18.5%, causing management to raise full-year guidance to 15-17%. This growth was supported by robust adoption in general surgery in the United States and accelerated utilization in emerging markets like India, Korea and the United Kingdom. The rollout of the da Vinci 5 platform continued at pace, with 147 new systems placed and over 32,000 procedures completed using the new-generation robot. However, this clinical and procedural strength faces growing financial headwinds. Gross margins declined to 66.4% in the first quarter from 67.6% a year ago due to increased depreciation, a higher mix of lower-margin platforms like Ion and da Vinci 5, and emerging cost pressures from newly implemented global tariffs. ISRG now expects tariff-driven cost of sales to erode margins by approximately 170 basis points for the full year, revising its gross margin forecast to 65-66.5%. While recurring revenues remain strong, representing 85% of the total revenues, capital expenditures, manufacturing investments and rising input costs may challenge operating leverage in the near term. Moreover, constrained hospital budgets in key markets like Germany and Japan could tamper the company's capital placement run rate, adding another layer of margin pressure. Intuitive Surgical's solid procedure growth and market adoption are commendable, but they will be tested against a backdrop of tightening margins, macroeconomic headwinds and evolving trade dynamics. Investors should watch closely whether strong volume momentum can continue to outrun inflationary and structural cost drags in the quarters ahead. Improving Margin for ISRG's Rivals In the first quarter of 2025, Stryker SYK posted strong financials, with organic sales growth of 10.1% and total revenues reaching $5.87 billion, reflecting an 11.9% year-over-year rise. This was driven by robust demand across MedSurg & Neurotechnology and Orthopaedics segments, including standout growth in trauma and extremities, and expanding Mako installations. Stryker's adjusted gross margin was 65.5%, up 190 basis points year over year, aided by manufacturing efficiencies, favorable pricing and product mix. Despite a $200 million tariff headwind expected for the year, Stryker maintained operating margin expansion of 100 basis points, reflecting strong cost control and operational leverage. In contrast, Medtronic MDT reported 3.9% year-over-year revenue growth in the fourth quarter of fiscal 2025 (to $8.93 billion), with strength in Cardiovascular (up 22% in cardiac ablation), Neuroscience, and Diabetes offsetting surgical headwinds. Medtronic's gross margin improved to 64.7% (up 19 basis points) and operating margin rose to 26.6%, buoyed by pricing strategies and cost-of-goods-sold productivity gains. However, growth remained uneven across Medtronic's portfolios. ISRG's Price Performance, Valuation and Estimates Shares of ISRG have gained 0.1% in the year-to-date period against the industry 's decline of 11.4%. Image Source: Zacks Investment Research From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 62.09, above the industry average. But, it is still lower than its five-year median of 72.17. ISRG carries a Value Score of D. The Zacks Consensus Estimate for Intuitive Surgical's 2025 earnings implies a 6.8% rise from the year-ago period's level. The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Medtronic PLC (MDT): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Yahoo
5 days ago
- Business
- Yahoo
ForSight Robotics raises $125m for cataract surgery robotic platform
Israel-based ForSight Robotics has completed a Series B funding round, raising $125m to fuel the growth phase of the robotic surgery platform intended for cataract and other eye conditions. Claimed to be a world first, the ORYOM platform is tailored to reduce the physical load on surgeons and improve surgical precision. ForSight is gearing up to introduce first-in-human trials within the year. Spearheaded by Eclipse, the round also included substantial contributions from an undisclosed investor, alongside Intuitive Surgical founder Dr Fred Moll, Reiya Ventures, the Adani Group, and other current investors. This latest financial injection brings the company's total funding to $195m. ForSight noted that the platform leverages AI-based algorithms, computer vision, and micromechanics to provide manoeuvrability and dexterity. Capable of reaching any point in the human eye, the platform claims to facilitate navigation through difficult angles and ensures access to anterior and posterior segments, enabling future glaucoma and retinal surgical treatments. Using the platform, more than 24 ophthalmic surgeons have already performed several procedures on animal eye models. The company plans to begin robotic cataract surgery clinical trials in the upcoming year. ForSight Robotics' chief medical officer, president, and co-founder Dr Joseph Nathan said: 'We see ophthalmology as the next frontier in the robotics revolution – much like general surgery was before the rise of Intuitive Surgical. With a comparable market size and an urgent global need, our opportunity ahead is immense. 'Through our latest funding round, we will bring the same level of transformative impact to eye surgery, with technology designed specifically for its unique precision and complexity.' ForSight has formed a strategic advisory board comprising leaders in surgical robotics. They include MAKO Surgical Corp founder Rony Abovitz and Dr Fred Moll, who recently joined ForSight's board of directors. "ForSight Robotics raises $125m for cataract surgery robotic platform" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
6 days ago
- Business
- Yahoo
Intuitive Surgical, Inc. (ISRG): A Bull Case Theory
We came across a bullish thesis on Intuitive Surgical, Inc. (ISRG) on PitchStack Investing's Substack. In this article, we will summarize the bulls' thesis on ISRG. Intuitive Surgical, Inc. (ISRG)'s share was trading at $513 as of 12th June. ISRG's trailing and forward P/E were 76.49 and 67.11 respectively according to Yahoo Finance. Close-up of a robotic endoluminal surgery device performing a procedure in an operating room. Intuitive Surgical stands as a dominant force in the field of robotic-assisted surgery, leveraging decades of innovation to maintain a commanding 90% market share in this high-growth sector. The company continues to enhance minimally invasive care through its advanced technologies, most notably the Ion system, which delivers an 83% diagnostic yield for small lung nodules—far surpassing traditional manual methods. This superior performance not only positions Ion for broader adoption in pulmonary care but also adds a meaningful growth vector to Intuitive's already robust platform. The widespread acceptance of the company's systems across hospitals worldwide reinforces its competitive moat, making it exceedingly difficult for new entrants to gain traction. Investors looking for sustained long-term growth may find the current setup compelling: analysts project a 115% stock price increase over the next five years, implying a 17% internal rate of return. This growth potential is grounded in a combination of expanding procedure volumes, continuous product innovation, and a razor-and-blade business model that ensures recurring revenue through instruments and service. Intuitive's entrenched position in hospitals, proven clinical efficacy, and ongoing investments in next-generation systems provide a strong foundation for continued leadership in surgical robotics. As healthcare systems globally prioritize better outcomes and operational efficiency, Intuitive Surgical is uniquely positioned to benefit from this secular shift, offering investors a rare blend of resilience, technological leadership, and upside. Previously, we covered a on ISRG by The Antifragile Investor in January 2025, focusing on its da Vinci-driven moat, IP edge, and recurring revenue. PitchStack Investing shares this view but emphasizes growth—citing Ion's clinical advantage, 90% market share, and a 17% IRR forecast. Both see a leader, but one stresses defensibility, the other, accelerating upside. Intuitive Surgical, Inc. (ISRG) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 106 hedge fund portfolios held Intuitive Surgical, Inc. (ISRG) at the end of the first quarter which was 95 in the previous quarter. While we acknowledge the risk and potential of ISRG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
6 days ago
- Business
- Associated Press
cultivate(MD) Announces Portfolio Company, Virtual Incision Corporation, Appoints Jim Alecxih as Chief Executive Officer
GRAND RAPIDS, Mich., June 24, 2025 /PRNewswire/ -- cultivate(MD), a leading medical device venture capital company, is pleased to announce that its portfolio company, Virtual Incision Corporation, the developer of the MIRA Surgical System authorized by the FDA through the De Novo regulatory pathway, has appointed Jim Alecxih as Chief Executive Officer. Alecxih, a recognized commercial leader in the medical device industry, brings more than 30 years of experience advancing transformative surgical technologies worldwide, including a distinguished tenure at Intuitive Surgical, where he played a pivotal role in the adoption and growth of the da Vinci Surgical System. Virtual Incision is now preparing for the accelerated development and commercialization of their next system, M2, with plans for a series of FDA submissions in various specialties. M2 is a miniaturized, single port surgical robotic system designed to be smart, simple and small, with the potential to minimize the cost and complexity of current mainframe cart-based surgical robotic systems. M2 will be optimized to bring robotic-assisted surgery to hospitals and surgical settings that lack access to surgical robotics technologies. Mr. Alecxih previously served as CEO of DH Medical, an AI software company, and has held executive leadership roles across multiple healthcare startups and growth-stage companies. At Intuitive Surgical, he led U.S. sales and was instrumental in driving adoption of robotic-assisted surgery among hospitals and health systems nationwide. 'The opportunity to lead Virtual Incision at this pivotal time is an extraordinary honor,' said Jim Alecxih, CEO of Virtual Incision. 'I believe deeply in the benefits of robotic-assisted surgery to both patients, surgeons and hospitals. M2 has the potential to dramatically expand access to robotic-assisted surgery in rural hospitals, Hospital Outpatient Department (HOPD) and Ambulatory Surgery Centers (ASC) settings, and around the world. Virtual Incision's visionary approach is to ensure that robotic-assisted surgery is more accessible, flexible and scalable for a broader range of operating environments. I'm thrilled to join this talented team and help accelerate our impact on patients and providers.' 'We are excited for this next significant phase and stage in the life of Virtual Incision's important journey to continue to bring 'MIRA', the miniature innovative robot, to the world,' said Dave Blue, Director, cultivate(MD) Capital Funds. Mr. Alecxih joins Virtual Incision at a time of significant momentum. In 2025, the company has been honored as a finalist or winner in three prestigious innovation awards: Virtual Incision's MIRA Surgical System is designed to offer a portable, scalable solution for minimally invasive procedures with a small footprint and a simple setup. With M2, the company aims to expand clinical capabilities and will continue redefining the future of robotic-assisted surgery. About cultivate(MD) cultivate(MD) is a medical device venture capital firm dedicated to advancing healthcare innovation. With a keen focus on cutting-edge medical technologies, cultivate(MD) supports companies that show the potential to revolutionize healthcare delivery and patient care. For more information, visit: About the MIRA Surgical System MIRA is the world's first miniaturized robotic-assisted surgery (RAS) system. Its small, sleek form factor is designed to offer the benefits of RAS during colectomy procedures without the logistical inefficiencies of traditional mainframe robotics. The easily accessible device weighs approximately two pounds (less than one kg) and offers internal triangulation with shoulders, arms, and infinite wrist roll inside of the body. It can be used in any operating room – a dedicated operating room is unnecessary. With its drape- and dock-free design and portability, MIRA is quick to set up, clean up, and move between cases. Its conveniently accessible design positions it to be used as a standalone system or a complementary tool for facilities that already own a legacy surgical robotic system. With MIRA, every operating room is RAS-ready. About Virtual Incision Virtual Incision is on a mission to simplify robotic-assisted surgery (RAS), so more patients and their surgeons can access its benefits every day. Headquartered in Lincoln, Nebraska, and holding over two hundred patents and patent applications, the company developed MIRA, the first-of-its-kind miniature RAS system. Virtual Incision's goal is to make every operating room RAS-ready. For more information, visit: Cautionary Note Regarding Forward-Looking Statements This communication contains statements that constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to, statements regarding our plans, beliefs, expectations, assumptions, and other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date on which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. View original content to download multimedia: SOURCE cultivate(MD)
Yahoo
6 days ago
- Business
- Yahoo
cultivate(MD) Announces Portfolio Company, Virtual Incision Corporation, Appoints Jim Alecxih as Chief Executive Officer
GRAND RAPIDS, Mich., June 24, 2025 /PRNewswire/ -- cultivate(MD), a leading medical device venture capital company, is pleased to announce that its portfolio company, Virtual Incision Corporation, the developer of the MIRA Surgical System authorized by the FDA through the De Novo regulatory pathway, has appointed Jim Alecxih as Chief Executive Officer. Alecxih, a recognized commercial leader in the medical device industry, brings more than 30 years of experience advancing transformative surgical technologies worldwide, including a distinguished tenure at Intuitive Surgical, where he played a pivotal role in the adoption and growth of the da Vinci Surgical System. Virtual Incision is now preparing for the accelerated development and commercialization of their next system, M2, with plans for a series of FDA submissions in various specialties. M2 is a miniaturized, single port surgical robotic system designed to be smart, simple and small, with the potential to minimize the cost and complexity of current mainframe cart-based surgical robotic systems. M2 will be optimized to bring robotic-assisted surgery to hospitals and surgical settings that lack access to surgical robotics technologies. Mr. Alecxih previously served as CEO of DH Medical, an AI software company, and has held executive leadership roles across multiple healthcare startups and growth-stage companies. At Intuitive Surgical, he led U.S. sales and was instrumental in driving adoption of robotic-assisted surgery among hospitals and health systems nationwide. "The opportunity to lead Virtual Incision at this pivotal time is an extraordinary honor," said Jim Alecxih, CEO of Virtual Incision. "I believe deeply in the benefits of robotic-assisted surgery to both patients, surgeons and hospitals. M2 has the potential to dramatically expand access to robotic-assisted surgery in rural hospitals, Hospital Outpatient Department (HOPD) and Ambulatory Surgery Centers (ASC) settings, and around the world. Virtual Incision's visionary approach is to ensure that robotic-assisted surgery is more accessible, flexible and scalable for a broader range of operating environments. I'm thrilled to join this talented team and help accelerate our impact on patients and providers." "We are excited for this next significant phase and stage in the life of Virtual Incision's important journey to continue to bring "MIRA", the miniature innovative robot, to the world," said Dave Blue, Director, cultivate(MD) Capital Funds. Mr. Alecxih joins Virtual Incision at a time of significant momentum. In 2025, the company has been honored as a finalist or winner in three prestigious innovation awards: Fast Company's World's Most Innovative Companies SXSW Innovation Award Fierce MedTech's Fierce 15 Virtual Incision's MIRA Surgical System is designed to offer a portable, scalable solution for minimally invasive procedures with a small footprint and a simple setup. With M2, the company aims to expand clinical capabilities and will continue redefining the future of robotic-assisted surgery. About cultivate(MD)cultivate(MD) is a medical device venture capital firm dedicated to advancing healthcare innovation. With a keen focus on cutting-edge medical technologies, cultivate(MD) supports companies that show the potential to revolutionize healthcare delivery and patient care. For more information, visit: About the MIRA Surgical SystemMIRA is the world's first miniaturized robotic-assisted surgery (RAS) system. Its small, sleek form factor is designed to offer the benefits of RAS during colectomy procedures without the logistical inefficiencies of traditional mainframe robotics. The easily accessible device weighs approximately two pounds (less than one kg) and offers internal triangulation with shoulders, arms, and infinite wrist roll inside of the body. It can be used in any operating room – a dedicated operating room is unnecessary. With its drape- and dock-free design and portability, MIRA is quick to set up, clean up, and move between cases. Its conveniently accessible design positions it to be used as a standalone system or a complementary tool for facilities that already own a legacy surgical robotic system. With MIRA, every operating room is RAS-ready. About Virtual IncisionVirtual Incision is on a mission to simplify robotic-assisted surgery (RAS), so more patients and their surgeons can access its benefits every day. Headquartered in Lincoln, Nebraska, and holding over two hundred patents and patent applications, the company developed MIRA, the first-of-its-kind miniature RAS system. Virtual Incision's goal is to make every operating room RAS-ready. For more information, visit: Cautionary Note Regarding Forward-Looking Statements This communication contains statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to, statements regarding our plans, beliefs, expectations, assumptions, and other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date on which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. View original content to download multimedia: SOURCE cultivate(MD) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
